{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:22:29Z","timestamp":1793229749093,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K99 CA276804"],"award-info":[{"award-number":["K99 CA276804"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA232130-04"],"award-info":[{"award-number":["R35 CA232130-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD016207-01"],"award-info":[{"award-number":["S10 OD016207-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA08748"],"award-info":[{"award-number":["P30 CA08748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) is frequently diagnosed at late stages after metastasis and chemorefractive leading to poor survival outcomes. There is a critical need for earlier detection and novel antigen-targeted therapies to improve patient survival at all stages. TROP-2 is a transmembrane glycoprotein overexpressed in many cancers and presents a promising target for OC. Recently, antibody-drug conjugates such as sacituzumab govitecan (SG) and datopotamab deruxtecan have been approved for various TROP-2-positive malignancies such as metastatic breast, lung, or urothelial cancer. However, diagnosis is based on prior therapy failure and TROP-2 therapy focused on antibody-drug conjugates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Minimal radiotheranostic versions of SG were developed for immunoPET imaging with [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-SG in flank and intraperitoneal OVCAR3 implants. IHC was also done to identify other OC models that express Trop2. Radiotherapy variants of SG [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DTPA-SG, [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-mcp-Direct-SG, or [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-mcp-Click-SG were also made and tested for efficacy alongside the standard of care SG.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DTPA-SG delayed tumor recurrence for up 6\u20138 weeks post-treatment and retreatment prolonged overall survival to 21 weeks matching standard of care SG dosing. Between two linkers, [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-mcp-Direct-SG was found to yield a superior minimal conjugation of SG than [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-mcp-Click-SG, with better tumor targeting by biodistribution and prolonged reduction in OC over 30 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Ultimately, utility of SG was improved through minimal modification of the ADC and applied a \u201ctreat what you see\u201d approach to TROP-2-positive OC. By using a new tetrafluorophenyl linkage of macropa, [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-mcp-Direct-SG greatly reduced tumor burden in OC with most mice surviving and tolerating the therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07820-7","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:02:39Z","timestamp":1772240559000},"page":"4587-4596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Minimal chemical modification enables alpha\/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Angelique","family":"Loor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeara N.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin C.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"1","key":"7820_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"7820_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.5306\/wjco.v11.i11.868","volume":"11","author":"L Feeney","year":"2020","unstructured":"Feeney L, et al. Liquid biopsy in ovarian cancer: catching the silent killer before it strikes. World J Clin Oncol. 2020;11(11):868\u201389.","journal-title":"World J Clin Oncol"},{"key":"7820_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"issue":"1","key":"7820_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, et al. Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7820_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","volume":"34","author":"G Bogani","year":"2024","unstructured":"Bogani G, et al. Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024;34(4):469\u201377.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"7820_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, et al. Phase III, randomized trial of Mirvetuximab Soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757\u201365.","journal-title":"Ann Oncol"},{"key":"7820_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","volume":"75","author":"BE Nelson","year":"2024","unstructured":"Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug conjugates in solid tumors. Annu Rev Med. 2024;75:31\u201348.","journal-title":"Annu Rev Med"},{"key":"7820_CR8","doi-asserted-by":"crossref","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9.","DOI":"10.18632\/oncotarget.25615"},{"issue":"4","key":"7820_CR9","doi-asserted-by":"publisher","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188902.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7820_CR10","doi-asserted-by":"crossref","unstructured":"Lopez S, et al. Preclinical activity of sacituzumab Govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget. 2020;11:5.","DOI":"10.18632\/oncotarget.27342"},{"key":"7820_CR11","doi-asserted-by":"crossref","unstructured":"Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today. 2019;55(9):575-585.","DOI":"10.1358\/dot.2018.55.9.3039669"},{"key":"7820_CR12","doi-asserted-by":"crossref","unstructured":"Huang W et al. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2025;52(7):2369-2383.","DOI":"10.1007\/s00259-025-07106-4"},{"key":"7820_CR13","doi-asserted-by":"crossref","unstructured":"Huang W et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [(64)Cu]Cu-NOTA-Trodelvy-F(ab\u2019)(2). Eur J Nucl Med Mol Imaging. 2025;52(9):3223-3237.","DOI":"10.1007\/s00259-025-07167-5"},{"issue":"7","key":"7820_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.0c00087","volume":"32","author":"SK Sharma","year":"2021","unstructured":"Sharma SK, et al. A systematic evaluation of antibody modification and (89)Zr-Radiolabeling for optimized Immuno-PET. Bioconjug Chem. 2021;32(7):1177\u201391.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"7820_CR15","first-page":"3","volume":"11","author":"MR Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam MR, et al. Antibody-Drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11(1):3\u201323.","journal-title":"Avicenna J Med Biotechnol"},{"key":"7820_CR16","doi-asserted-by":"crossref","unstructured":"Mack KN et al. Interrogating the theranostic capacity of a MUC16-Targeted antibody for ovarian cancer. J Nucl Med. 2024;65(4):580-585.","DOI":"10.2967\/jnumed.123.266524"},{"key":"7820_CR17","doi-asserted-by":"crossref","unstructured":"Mack KN et al. Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. Nucl Med Biol. 2025;140\u20131:108976.","DOI":"10.1016\/j.nucmedbio.2024.108976"},{"issue":"19","key":"7820_CR18","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/cmdc.202100135","volume":"16","author":"N Herrero Alvarez","year":"2021","unstructured":"Herrero Alvarez N, et al. Recent advances in radiometals for combined imaging and therapy in cancer. ChemMedChem. 2021;16(19):2909\u201341.","journal-title":"ChemMedChem"},{"issue":"1","key":"7820_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.","journal-title":"J Hematol Oncol"},{"key":"7820_CR20","doi-asserted-by":"crossref","unstructured":"Bauer D et al. Examination of the PET in vivo generator (134)Ce as a theranostic match for (225)Ac. Eur J Nucl Med Mol Imaging. 2024;51:4015\u20134025.","DOI":"10.1007\/s00259-024-06811-w"},{"key":"7820_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","volume":"123","author":"L Marcu","year":"2018","unstructured":"Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol\/Hematol. 2018;123:7\u201320.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"6","key":"7820_CR22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41596-023-00825-8","volume":"18","author":"D Bauer","year":"2023","unstructured":"Bauer D, et al. Click chemistry: a transformative technology in nuclear medicine. Nat Protoc. 2023;18(6):1659\u201368.","journal-title":"Nat Protoc"},{"issue":"46","key":"7820_CR23","doi-asserted-by":"publisher","first-page":"14712","DOI":"10.1002\/anie.201709532","volume":"56","author":"NA Thiele","year":"2017","unstructured":"Thiele NA, et al. An Eighteen-Membered macrocyclic ligand for Actinium-225 targeted alpha therapy. Angew Chem Int Ed Engl. 2017;56(46):14712\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"7820_CR24","first-page":"183","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183\u2013203.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7820_CR25","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"7820_CR26","doi-asserted-by":"crossref","unstructured":"Huang W et al. Immuno-PET\/CT imaging of Trop2 with [(18)F]AlF-RESCA-T4 differentiates lung cancer from inflammation. J Nucl Med. 2024;65(12):1904-1910.","DOI":"10.2967\/jnumed.124.268751"},{"key":"7820_CR27","doi-asserted-by":"crossref","unstructured":"Pratt EC et al. Pretargeted Trop-2 ImmunoPET for rapid, selective detection of pancreatic tumors. Clin Cancer Res. 2025;31(13):2719\u20132726.","DOI":"10.1158\/1078-0432.CCR-24-3098"},{"issue":"2","key":"7820_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.20517\/cdr.2022.13","volume":"5","author":"MJ Flynn","year":"2022","unstructured":"Flynn MJ, Ledermann JA. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist. 2022;5(2):424\u201335.","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"7820_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-023-06454-3","volume":"51","author":"W Huang","year":"2024","unstructured":"Huang W, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51(2):380\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7820_CR30","doi-asserted-by":"crossref","unstructured":"Koltai T, Fliegel L. The relationship between Trop-2, chemotherapeutic Drugs, and chemoresistance. Int J Mol Sci. 2023;25(1):87.","DOI":"10.3390\/ijms25010087"},{"key":"7820_CR31","doi-asserted-by":"publisher","first-page":"115522","DOI":"10.1016\/j.ejca.2025.115522","volume":"224","author":"JM Porter","year":"2025","unstructured":"Porter JM, et al. Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer. Eur J Cancer. 2025;224:115522.","journal-title":"Eur J Cancer"},{"key":"7820_CR32","doi-asserted-by":"crossref","unstructured":"Bardia A et al. Final results from the randomized phase III ASCENT clinical trial in metastatic Triple-Negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42(15):1738-1744.","DOI":"10.1200\/JCO.23.01409"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07820-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:03:15Z","timestamp":1781636595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7820"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07820-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research from this manuscript with mice were conducted in accordance with IACUC guidelines under the approved protocol of Jason S. Lewis at MSKCC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"E.C.P. and J.S.L. have authored different works on TROP-2 antibody-based PET imaging using a proprietary TROP-2.2 antibody provided by Eli Lilly and Company through a sponsored research agreement. JSL and MSKCC have a licensed patent for US11135320B2 to Clarity Pharmaceuticals. The remaining authors from MSKCC declare no additional conflicts of interest beyond the sponsored research agreement. See the funding statement for all NIH grant support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}